The other point is that we have a much larger experience in this study and much longer follow up. So, I do think that we’re going to be able to look at the consistency of effect across both the monotherapy and the baseline TAP group. And that’s really what we’ll be focusing on as we look at that subgroup as well as a number of other subgroups in the study.
Yvonne Greenstreet: Excellent. Thank you.
Paul Matteis: Excellent. Thank you.
Operator: Thank you. And one moment for our next question. Our next question comes from Luca Issi of RBC. Your line is now open.
Lisa Munro: Oh, great. Thanks for taking our questions. This is Lisa on for Luca. I just want to touch base on HELIOS-B. Is it possible that you will elevate NT-proBNP and six-minute walk test as part of the composite primary endpoint? You obviously have shown promising results from both of those endpoints in the APOLLO-B, and in that way, if they’re elevated, you would have a primary endpoint that ends up replicating BridgeBio. So you could, in theory, use that as a regulatory precedent to facilitate your conversation with Norman Stockbridge. Would that be a fair way to think about it? Any color there would be much appreciated. Thanks.
Pushkal Garg: Thanks, Lisa, for your question. Look, I think what you’re pointing out and raising is the fact that when we looked at the APOLLO-B data, we did see really pretty much every endpoint lining up in favor of TTR lowering, whether it was functional like six-minute walk test or quality of life echocardiographic parameters, and biomarkers like NT-proBNP. And so I appreciate the point that you’re raising, and certainly, as Yvonne highlighted, we’re laser focused on delivering a successful study. We’re very confident in the overall design of the study, the execution of the study. I think to your point about the BridgeBio results, I think they point to the fact that in the modern era that this is still a progressive disease despite patients being caught earlier in their disease process, and that an effective therapy can show a benefit on top of that in that setting.
So we’re overall really encouraged by what the study is and how it’s designing out. And as we’ve mentioned, look, we’re laser focused on this. If there are any Tweaks adjustments that we make to the statistical analysis plan, we’ll follow up in due course.
Lisa Munro: Thanks.
Operator: Thank you. One moment for our next question. Ellie Merle of UBS, your line is now open.
Ellie Merle: Hey, guys, thanks so much for taking the question. Just, again, kind of on potential for combination. Just commercially, how are you thinking about the proportion of ATTR cardiomyopathy patients that will be treated with, say, monotherapy versus, say, a combination with tafamidis, assuming the success of HELIOS-B? And then just from a commercial perspective, what do you think payers want to see in terms of the benefit of vutrisiran on top of tafamidis, say, in terms of mortality, hospitalization, sort of anything coming out of any kind of initial conversations there? And then just a second, quick question. What data can we expect from the Phase 1 KHK data this year? And will the readout include weight loss data? Thanks.
Yvonne Greenstreet: Maybe we’ll take your first. We believe that AMVUTTRA is going to be a really important option for patients with the potential for a differentiated profile given its infrequent administration, minimal copays. And if you look at the progress that Tolga highlighted earlier with respect to the growth in patient demand for AMVUTTRA patients with probably, we believe that this is going to be a really important addition to the treatment armamentarium for physicians. Tolga maybe you could speak specifically to how we’re thinking about use with tafamidis.
